UroGen Pharma shares are trading higher after the company announced an 82.3% 12-month duration of response in its Phase 3 ENVISION trial for UGN-102, achieving a 79.6% complete response rate at three months.
Portfolio Pulse from Benzinga Newsdesk
UroGen Pharma shares are trading higher following the announcement of positive results from its Phase 3 ENVISION trial for UGN-102, showing an 82.3% 12-month duration of response and a 79.6% complete response rate at three months.
June 13, 2024 | 4:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
UroGen Pharma shares are trading higher after the company announced positive results from its Phase 3 ENVISION trial for UGN-102, with an 82.3% 12-month duration of response and a 79.6% complete response rate at three months.
The positive results from the Phase 3 ENVISION trial for UGN-102 are likely to boost investor confidence and drive the stock price higher in the short term. The high complete response rate and duration of response are significant milestones for the company.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100